• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Sep. 28, 2018

View Archived Issues

Rush to the market: Trio of biopharma IPOs prices as third quarter comes to a close

Arvinas Inc., Sutro Biopharma Inc. and Urovant Sciences Ltd. became the latest biopharmas to head to Nasdaq, pricing their IPOs to raise a combined $345 million, but – like Entasis Therapeutics Inc. a day earlier – not all enjoyed a warm welcome on their public debut. Read More

Akrevia Therapeutics launches with $30M series A

After years of seeing cancer immunotherapies fall short of their full potential, industry oncology veterans are taking a new tack. Under the banner of Akrevia Therapeutics Inc., they've put together a $30 million series A financing "with the aim of going big," Tim Clackson, president and head of R&D for the new venture, told BioWorld. Read More

Geron no mo': J&J gallops from imetelstat tie-up but phase III vision quest lives

Geron Corp.'s shares took a major hit as Johnson & Johnson unit Janssen Biotech Inc. ended their collaboration and license deal, leaving the telomerase inhibitor imetelstat to go it alone into the upcoming phase III trial. Read More

Bi-cycling in rare disease: Acer's candidate looking to grab Ravicti pie share

Gearing up for an NDA filing for selective adrenergic modulator Edsivo (celiprolol) in vascular Ehlers-Danlos syndrome (vEDS), Acer Therapeutics Inc. has begun drawing attention for another candidate in the pipeline: ACER-001 in urea cycle disorder (UCD), where company-watchers are placing bets on its odds of taking market share from the only approved therapy in the space, Ravicti (glycerol phenylbutyrate), from Horizon Pharma plc. Read More

Increasing globalization in biopharma highlights differing management styles, cultures

HONG KONG – The recent M&A deal between Japan's 237-year-old Takeda Pharmaceutical Co. Ltd. and Irish firm Shire plc has attracted massive attention, not just because of the mammoth size of the deal but also the tug of war among the Japanese company's shareholders, a group of which made a failed attempt to block the deal during Takeda's general meeting earlier this year. (See BioWorld, May 8, 2018.) Read More

Financings

Inmune Bio Inc., of La Jolla, Calif., filed with the SEC to offer a minimum of 1 million shares for gross proceeds of $8 million and a maximum of up to 2.5 million shares for gross proceeds of $20 million. Proceeds will support R&D activities of its Inkmune cancer program and other immuno-oncology efforts. Read More

Regulatory front

Citing a U.S. Supreme Court ruling that found the Racketeer Influenced and Corrupt Organizations Act (RICO) does not allow recovery for injuries suffered outside the U.S., the Third Circuit Court of Appeals affirmed a lower court's decision to dismiss a RICO action brought by Peter Humphrey and Yu Yingzeng, co-founders of Shanghai-based Chinawhys Co. Ltd., against Glaxosmithkline plc, of London.  Read More

Other news to note

Mithra Pharmaceuticals SA, of Liege, Belgium, said it finalized a contract with Chilean pharma Laboratorio Pasteur SA for an exclusive license and supply agreement to commercialize contraceptive product Myring in Chile. Under the terms of the 10-year contract, Mithra will be eligible for up-front and milestone payments, minimal annual quantities and further sales-related royalties. Read More

Clinical data for Sept. 27, 2018

Read More

Regulatory actions for Sept. 27, 2018

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 6, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 6, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • Biotech deal illustration

    City hits the town with $1B-plus deal with Biogen

    BioWorld
    A development deal with Biogen Inc. could eventually bring City Therapeutics Inc. about $1 billion in milestone payments. It’s a step in the direction the company...
  • Cancer cell in the cross-hairs

    Pan-cancer proteome atlas reveals new biomarkers and targets

    BioWorld Science
    An international group of scientists has completed the first draft of The Pan-Cancer Proteome Atlas (TPCPA). The project is based on mass spectrometry of 22...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe